Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Regional Differences in Intestinal Drug Metabolism.

Iswandana R, Irianti MI, Oosterhuis D, Hofker HS, Merema MT, de Jager MH, Mutsaers HA, Olinga P.

Drug Metab Dispos. 2018 Oct 1. pii: dmd.118.083428. doi: 10.1124/dmd.118.083428. [Epub ahead of print]

PMID:
30275119
2.

Human and rat precision-cut intestinal slices as ex vivo models to study bile acid uptake by the apical sodium-dependent bile acid transporter.

Li M, Vokral I, Evers B, de Graaf IAM, de Jager MH, Groothuis GMM.

Eur J Pharm Sci. 2018 May 9;121:65-73. doi: 10.1016/j.ejps.2018.05.005. [Epub ahead of print] No abstract available.

PMID:
29751102
3.

Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?

Ten Cate DF, Jacobs JWG, Swen WAA, Hazes JMW, de Jager MH, Basoski NM, Haagsma CJ, Luime JJ, Gerards AH.

Arthritis Res Ther. 2018 Jan 30;20(1):15. doi: 10.1186/s13075-018-1514-2.

4.

Anticancer Gold N-Heterocyclic Carbene Complexes: A Comparative in vitro and ex vivo Study.

Estrada-Ortiz N, Guarra F, de Graaf IAM, Marchetti L, de Jager MH, Groothuis GMM, Gabbiani C, Casini A.

ChemMedChem. 2017 Sep 7;12(17):1429-1435. doi: 10.1002/cmdc.201700316. Epub 2017 Aug 29.

PMID:
28741878
5.

The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.

Li M, de Graaf IA, van de Steeg E, de Jager MH, Groothuis GM.

Toxicol In Vitro. 2017 Apr;40:26-33. doi: 10.1016/j.tiv.2016.12.002. Epub 2016 Dec 7.

PMID:
27939799
6.

P-gp activity and inhibition in the different regions of human intestine ex vivo.

Li M, de Graaf IA, de Jager MH, Groothuis GM.

Biopharm Drug Dispos. 2017 Mar;38(2):127-138. doi: 10.1002/bdd.2047. Epub 2016 Nov 14.

PMID:
27757966
7.

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.

de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. Epub 2016 Aug 30.

PMID:
27581208
8.

The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.

Li M, de Graaf IA, Siissalo S, de Jager MH, van Dam A, Groothuis GM.

Drug Metab Dispos. 2016 May;44(5):683-91. doi: 10.1124/dmd.115.068684. Epub 2016 Mar 1.

9.

Rat precision-cut intestinal slices to study P-gp activity and the potency of its inhibitors ex vivo.

Li M, de Graaf IA, de Jager MH, Groothuis GM.

Toxicol In Vitro. 2015 Aug;29(5):1070-8. doi: 10.1016/j.tiv.2015.04.011. Epub 2015 Apr 25.

PMID:
25917215
10.

Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: synthesis and biological properties.

Bertrand B, Stefan L, Pirrotta M, Monchaud D, Bodio E, Richard P, Le Gendre P, Warmerdam E, de Jager MH, Groothuis GM, Picquet M, Casini A.

Inorg Chem. 2014 Feb 17;53(4):2296-303. doi: 10.1021/ic403011h. Epub 2014 Feb 5.

PMID:
24499428
11.

Nanoparticle formulation of a poorly soluble cannabinoid receptor 1 antagonist improves absorption by rat and human intestine.

Siissalo S, de Waard H, de Jager MH, Hayeshi R, Frijlink HW, Hinrichs WL, Dinter-Heidorn H, van Dam A, Proost JH, Groothuis GM, de Graaf IA.

Drug Metab Dispos. 2013 Aug;41(8):1557-65. doi: 10.1124/dmd.112.049585. Epub 2013 Jun 3.

12.

Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis--a systematic review of the literature.

Ten Cate DF, Luime JJ, Swen N, Gerards AH, De Jager MH, Basoski NM, Hazes JM, Haagsma CJ, Jacobs JW.

Arthritis Res Ther. 2013 Jan 8;15(1):R4. doi: 10.1186/ar4132. Review.

13.

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.

de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Ann Rheum Dis. 2013 Jan;72(1):72-8. doi: 10.1136/annrheumdis-2011-201162. Epub 2012 Jun 7.

PMID:
22679301
14.

Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.

de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, Luime JJ, Weel AE.

Rheumatology (Oxford). 2012 Jul;51(7):1269-77. doi: 10.1093/rheumatology/kes008. Epub 2012 Feb 29.

PMID:
22378716
15.

Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies.

de Graaf IA, Olinga P, de Jager MH, Merema MT, de Kanter R, van de Kerkhof EG, Groothuis GM.

Nat Protoc. 2010 Sep;5(9):1540-51. doi: 10.1038/nprot.2010.111. Epub 2010 Aug 19.

PMID:
20725069
16.

Reduced ischemia-reoxygenation injury in rat intestine after luminal preservation with a tailored solution.

Roskott AM, Nieuwenhuijs VB, Leuvenink HG, Dijkstra G, Ottens P, de Jager MH, Gonalves Dias Pereira P, Fidler V, Groothuis GM, Ploeg RJ, de Graaf IA.

Transplantation. 2010 Sep 27;90(6):622-9. doi: 10.1097/TP.0b013e3181ebf796.

PMID:
20689496
17.

Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BA.

Ann Rheum Dis. 2007 Sep;66(9):1227-32. Epub 2007 Apr 3.

18.

Induction of phase I and II drug metabolism in rat small intestine and colon in vitro.

van de Kerkhof EG, de Graaf IA, de Jager MH, Groothuis GM.

Drug Metab Dispos. 2007 Jun;35(6):898-907. Epub 2007 Mar 7.

19.

Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations.

van de Kerkhof EG, Ungell AL, Sjöberg AK, de Jager MH, Hilgendorf C, de Graaf IA, Groothuis GM.

Drug Metab Dispos. 2006 Nov;34(11):1893-902. Epub 2006 Aug 16.

20.

Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction.

de Graaf IA, de Kanter R, de Jager MH, Camacho R, Langenkamp E, van de Kerkhof EG, Groothuis GM.

Drug Metab Dispos. 2006 Apr;34(4):591-9. Epub 2006 Jan 13.

21.

Characterization of rat small intestinal and colon precision-cut slices as an in vitro system for drug metabolism and induction studies.

van de Kerkhof EG, de Graaf IA, de Jager MH, Meijer DK, Groothuis GM.

Drug Metab Dispos. 2005 Nov;33(11):1613-20. Epub 2005 Jul 28.

22.

A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies.

de Kanter R, Tuin A, van de Kerkhof E, Martignoni M, Draaisma AL, de Jager MH, de Graaf IA, Meijer DK, Groothuis GM.

J Pharmacol Toxicol Methods. 2005 Jan-Feb;51(1):65-72.

PMID:
15596116
23.

Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon.

De Kanter R, Monshouwer M, Draaisma AL, De Jager MH, de Graaf IA, Proost JH, Meijer DK, Groothuis GM.

Xenobiotica. 2004 Mar;34(3):229-41.

PMID:
15204696
24.

Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices.

De Kanter R, De Jager MH, Draaisma AL, Jurva JU, Olinga P, Meijer DK, Groothuis GM.

Xenobiotica. 2002 May;32(5):349-62.

PMID:
12065058
25.

Rat liver slices as a tool to study LPS-induced inflammatory response in the liver.

Olinga P, Merema MT, de Jager MH, Derks F, Melgert BN, Moshage H, Slooff MJ, Meijer DK, Poelstra K, Groothuis GM.

J Hepatol. 2001 Aug;35(2):187-94.

PMID:
11580140
26.

The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake.

Olinga P, Hof IH, Merema MT, Smit M, de Jager MH, Swart PJ, Slooff MJ, Meijer DK, Groothuis GM.

J Pharmacol Toxicol Methods. 2001 Jan-Feb;45(1):55-63.

PMID:
11489665
27.

Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney.

De Kanter R, Olinga P, De Jager MH, Merema MT, Meijer DK, Groothius GM.

Toxicol In Vitro. 1999 Aug-Oct;13(4-5):737-44.

PMID:
20654543
28.

Effect of cold and warm ischaemia on drug metabolism in isolated hepatocytes and slices from human and monkey liver.

Olinga P, Merema MT, Hof IH, De Jager MH, De Jong KP, Slooff MJ, Meijer DK, Groothuis GM.

Xenobiotica. 1998 Apr;28(4):349-60.

PMID:
9604299
29.

Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans cells.

Teunissen MB, De Jager MH, Kapsenberg ML, Bos JD.

Br J Dermatol. 1991 Oct;125(4):309-16.

PMID:
1954118
30.

Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage.

Boucher CA, de Jager MH, Debouck C, Epstein LG, de Wolf F, Wolfs TF, Goudsmit J.

J Clin Microbiol. 1989 Jul;27(7):1577-81. Erratum in: J Clin Microbiol 1989 Nov;27(11):2626.

Supplemental Content

Loading ...
Support Center